Outlook Therapeutics, Inc. (OTLK) — 10-Q Filings

10-Q Filings (6)

• Outlook Therapeutics Launches LYTENAVA, Faces Going Concern Doubts — Aug 14, 2025 Risk: high
  Outlook Therapeutics, Inc. (OTLK) reported net revenues of $1,505,322 for the three and nine months ended June 30, 2025, a significant increase from zero revenu
• Outlook Therapeutics Files 10-Q for Q2 2025 — May 15, 2025 Risk: medium
  Outlook Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Oncobiologics, Inc., reported financial data for
• Outlook Therapeutics Reports Q2 Loss, Focus on ONS-5010 — Feb 14, 2025 Risk: high
  Outlook Therapeutics, Inc. filed its 10-Q for the period ending December 31, 2024. The company reported a net loss of $23.9 million for the three months ended D
• Outlook Therapeutics Reports Q3 Loss, Cash Position — Aug 14, 2024 Risk: high
  Outlook Therapeutics, Inc. reported a net loss of $13.0 million for the third quarter of fiscal year 2024, compared to a net loss of $23.4 million in the same p
• Outlook Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: medium
  Outlook Therapeutics, Inc. (OTLK) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Outlook Therapeutics, Inc. filed a 10-Q for the period ending Ma
• Outlook Therapeutics, Inc. Files 10-Q for Period Ending December 31, 2023 — Feb 14, 2024 Risk: medium
  Outlook Therapeutics, Inc. (OTLK) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. Outlook Therapeutics, Inc. reported financial results for t

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX